Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction.
about
Biomarkers in heart failure with preserved ejection fractionB-type natriuretic peptide-guided treatment for heart failure.Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction.Pattern of endothelial progenitor cells and apoptotic endothelial cell-derived microparticles in chronic heart failure patients with preserved and reduced left ventricular ejection fractionPhenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Differentiating heart failure phenotypes using sex-specific transcriptomic and proteomic biomarker panels.The current status of heart failure diagnostic biomarkers.Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives.Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction.Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides.A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure.Troponin T elevation after permanent pacemaker implantation.A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF.Performance of AHEAD Score in an Asian Cohort of Acute Heart Failure With Either Preserved or Reduced Left Ventricular Systolic Function.Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction.Extracellular Vesicles as Protagonists of Diabetic Cardiovascular Pathology.Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial.Association between cystatin C and heart failure with preserved ejection fraction in elderly Chinese patients.Renal dysfunction in heart failure with a preserved ejection fraction: cause or consequence?Early-onset preeclampsia predisposes to preclinical diastolic left ventricular dysfunction in the fifth decade of life: An observational study.Prognostication in Different Heart Failure Phenotypes: The Role of Circulating Biomarkers.Plasma Circulating Extracellular RNAs in Left Ventricular Remodeling Post-Myocardial Infarction.Novel concept to guide systolic heart failure medication by repeated biomarker testing-results from TIME-CHF in context of predictive, preventive, and personalized medicine.Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction.Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview.
P2860
Q26768192-CA72B714-6182-400E-89A2-921F919714E8Q30238936-18215003-72E2-4233-B52B-413D2D056648Q36171125-DA94EBD3-F268-4B0B-84D8-EC9F3EA4A1E6Q36645079-2D0C1A1B-251D-4ACA-8851-8F59324C5505Q37058596-104E8693-5BC2-4E35-B04E-1B2E18B1F745Q38643995-455425C3-962A-49B0-A2E5-3079B3E0C358Q38703882-30643301-B427-414A-8810-660B5059140BQ38756838-4A53407D-189E-4A9C-8AFD-F27FA15E646BQ39127729-34808524-0F0E-4E5D-9E7D-D66C4FEE9D44Q39192295-9094D1A4-1AE6-4928-BF1C-59299249B6B3Q40150029-B5678206-8040-43D0-A0E0-C5DE3A10D2FDQ40247825-B6AA4D91-A9B7-4A7A-8AEB-044F857B4C4CQ40777024-F6EA1E54-4F1D-44C5-BA05-48BE47EDA931Q41104192-44F29836-6F73-4AD3-9E89-628A9D070CA0Q41165768-4C7E05CF-F80F-46E1-B08E-EC9B4D3AF8F7Q47138160-7745E2E9-1568-46F3-A1B3-240164C9294FQ48310286-47346086-1090-4180-B471-D6CEE8C1CD76Q48721801-64617E24-19D4-46FA-AA76-9CF17AC1877FQ54320351-E8821B8D-8A07-4F6F-9539-9BD204654CC1Q55332174-E2DBEA85-800A-499E-BF81-05278AC0153DQ55343200-EC4435AA-9EBE-47AF-A655-F12E1CB51692Q55381244-D8CE76BE-B18E-4BE4-891E-EDD8E494B0E2Q55409538-D2662579-4EB8-4BBA-9AA4-CC38E0CDD8BDQ55499529-26ECA121-4ACC-4298-AC09-F122BEC777D6Q55610979-8FB09E40-666B-4762-A68E-CC3C61E27919
P2860
Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Circulating biomarkers of dist ...... ventricular ejection fraction.
@en
Circulating biomarkers of dist ...... ventricular ejection fraction.
@nl
type
label
Circulating biomarkers of dist ...... ventricular ejection fraction.
@en
Circulating biomarkers of dist ...... ventricular ejection fraction.
@nl
prefLabel
Circulating biomarkers of dist ...... ventricular ejection fraction.
@en
Circulating biomarkers of dist ...... ventricular ejection fraction.
@nl
P2093
P2860
P356
P1476
Circulating biomarkers of dist ...... ventricular ejection fraction.
@en
P2093
Matthias E Pfisterer
Micha T Maeder
Nasser Davarzani
Rolf Handschin
Sandra Sanders-van Wijk
TIME-CHF investigators
Vanessa van Empel
P2860
P304
P356
10.1002/EJHF.414
P577
2015-10-16T00:00:00Z